ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations

Moral-Sanz, Javier, Fernandez-Rojo, Manuel A., Potriquet, Jeremy, Mukhopadhyay, Pamela, Brust, Andreas, Wilhelm, Patrick, Smallwood, Taylor B., Clark, Richard J., Fry, Bryan G., Alewood, Paul F., Waddell, Nicola, Miles, John J., Mulvenna, Jason P., and Ikonomopoulou, Maria P. (2021) ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations. Toxins, 13 (2). 146.

[img]
Preview
PDF (Published Version) - Published Version
Available under License Creative Commons Attribution.

Download (4MB) | Preview
View at Publisher Website: https://doi.org/10.3390/toxins13020146
 
2
47


Abstract

Melanoma is the main cause of skin cancer deaths, with special emphasis in those cases carrying BRAF mutations that trigger the mitogen-activated protein kinases (MAPK) signaling and unrestrained cell proliferation in the absence of mitogens. Current therapies targeting MAPK are hindered by drug resistance and relapse that rely on metabolic rewiring and Akt activation. To identify new drug candidates against melanoma, we investigated the molecular mechanism of action of the Octopus Kaurna-derived peptide, Octpep-1, in human BRAF(V600E) melanoma cells using proteomics and RNAseq coupled with metabolic analysis. Fluorescence microscopy verified that Octpep-1 tagged with fluorescein enters MM96L and NFF cells and distributes preferentially in the perinuclear area of MM96L cells. Proteomics and RNAseq revealed that Octpep-1 targets PI3K/AKT/mTOR signaling in MM96L cells. In addition, Octpep-1 combined with rapamycin (mTORC1 inhibitor) or LY3214996 (ERK1/2 inhibitor) augmented the cytotoxicity against BRAF(V600E) melanoma cells in comparison with the inhibitors or Octpep-1 alone. Octpep-1-treated MM96L cells displayed reduced glycolysis and mitochondrial respiration when combined with LY3214996. Altogether these data support Octpep-1 as an optimal candidate in combination therapies for melanoma BRAF(V600E) mutations.

Item ID: 70527
Item Type: Article (Research - C1)
ISSN: 2072-6651
Keywords: cancer, combination-therapies, melanoma BRAF mutation, octopus-peptide, venom-peptide
Copyright Information: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/)
Date Deposited: 03 May 2022 00:45
Downloads: Total: 47
Last 12 Months: 47
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page